Skip to content

St. Joe's Invitation Effectiveness Study

Increasing Cervical Cancer Screening Among Female Patients at Penn State Health St. Joe's Residency Clinic: Letter Notifying Them About Outdated Screen and Postcard With Self-sampling Option

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04658888
Enrollment
964
Registered
2020-12-09
Start date
2021-04-26
Completion date
2022-02-01
Last updated
2022-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer Screening

Keywords

Cervical Cancer, Self-Sampling

Brief summary

The objective of this study is to evaluate the effectiveness of offering self-sampling for high risk human papilloma virus (HPV) testing in order to increase the number of women who are screened for cervical cancer. The hypothesis of this study is that women who are notified of a need for cervical cancer screening by letter and are also offered a self-sampling kit for cervical cancer screening will have a higher rate of screening than women notified by letter alone. This study will use an intervention arm (letter and option to request a self-sampling kit) compared to a control arm (letter alone, standard of care) as a reminder that they are out of date for their cervical cancer screening. Women who are out of date with their cervical cancer screening will be identified using the Electronic Medical Record and randomized to the study group in a 2 to 1 ratio (2 for the control arm and 1 to the intervention arm). The primary endpoint that will be evaluated in this study is the method of completion of cervical cancer screening and the use of the self-sampling kit, which will be monitored over a three month period after the letters have been mailed. A secondary endpoint will be the overall rate of cervical cancer screening of all people mailed a letter.

Detailed description

The American Cancer Society estimates that 4,170 women in the United States will die from cervical cancer in 2018. It is possible to prevent many of these deaths through screening and appropriate follow-up in women with positive screens (1). Self-sampling for HPV testing may be a viable option for cervical cancer screening, particularly among women who do not obtain regular screening in a clinical setting. The objective of this study is to evaluate the effectiveness of offering self-sampling for high risk HPV testing to in order to increase the number of women who are screened for cervical cancer at the Penn State Health (PSH) St. Joseph's family and community medicine residency clinic. This study will use an intervention arm and a control arm. Women in the control arm will receive a standard letter stating that they need to be screened and should contact their primary care provider. Women in the intervention arm will receive a modified version of the letter informing them of a self-sampling option with a pre-addressed post card that allows them to request a self-sampling kit. Once the postcard is returned these women will receive a self-sampling kit in the mail to collect their sample. The kit will come with a pre-paid mailer so that the participant can return their kit for processing at the Penn State Hershey Clinical laboratory. Women who are out of date with their cervical cancer screening will be identified using the Electronic Medical Record by the use of a set of queries that have been developed to extract this patient population. Eligible women will be randomized to the study group in a 2 to 1 ratio (2 for the control arm and 1 to the intervention arm). The primary endpoint that will be evaluated in this study is the method of completion of cervical cancer screening and the use of the self-sampling kit, which will be monitored over a three month period after the letters have been mailed. A secondary endpoint will be the overall rate of cervical cancer screening of all people mailed a letter. Participants will be recruited continuously until the anticipated sample size has been met. A total of 1,211 participants are expected to participate in this study, 807 in the control arm and 404 in the intervention arm. The study team will calculate the proportion of participants who obtain cervical cancer screening from the clinic or the self-sampling kit and use chi-square tests for statistical analysis. If a self-collected cervical sample produces a negative result, the participant will be contacted by a study physician with these results. If the sample produces a positive result for low-risk HPV the participant will be contacted by a study physician to schedule a pap test. If the sample produces a positive result for high-risk HPV the participant will be contacted by a study physician for a colposcopy. The pap test and colposcopy are both standard of care for these results. The study team will monitor the completion of the screenings and subsequent procedures.

Interventions

A self-sampling brush to collect cervical cancer cells for screening purposes.

Sponsors

Milton S. Hershey Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Intervention model description

This study will use a two armed model: an intervention and a control arm. The control arm will use a standard of care letter reminding the participant to schedule their screening with their primary care provider. The intervention arm will consist of a modified letter with a postcard giving the participant the option to request a self-sampling kit.

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Female patients at Penn State Health St. Joe's Family and Community Medicine residency clinic or women's health clinic. * Ages 30-65 years * Out-of-date for cervical cancer screening * Able to speak, read, and communicate well in English or Spanish * Not greater than average risk for cervical cancer screening

Exclusion criteria

* Pregnant * Incarcerated * Greater than average risk for cervical cancer (2) * Have a compromised immune system * With in-utero exposure to diethylstilbestrol * Unable to speak, read, and communicate well in English or Spanish * Unable or unwilling to give implied consent or otherwise complete study requirements

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Cervical Cancer ScreeningThree months after the letter is sent.To compare the percentage of cervical cancer screenings completed in the control group who received a standard letter with the percentage of cervical cancer screenings completed in the intervention group who receive a modified letter with a self-sampling option.
Use of the Self-sampling KitThree months after the letter is sentEvaluate the number of participants request and use the self-sampling kit in the intervention group.

Secondary

MeasureTime frameDescription
Overall Rate of Cervical Cancer Screening Over Both the Control and Intervention GroupThree months after the letter is sentOverall rate of cervical cancer screenings for both the control group and the intervention group.

Countries

United States

Participant flow

Recruitment details

A report from the electronic medical record identified woman ages 30-65 who were out of date for cervical cancer screening. Letters were sent to the patient's home during June-July 2021.

Pre-assignment details

No participants who qualified were excluded from the study.

Participants by arm

ArmCount
Modified Letter With Self-sampling Request Card
This group received a modified letter telling the participant they are out of date with their cervical cancer screening. They also received information on the self-sampling kit and were provided a card that they can send back to the study team in order to have a kit sent to their house. The kit included a pre-paid mailer so that it can be sent back to the lab for testing. Evalyn Self-Sampling Brush: A self-sampling brush to collect cervical cancer cells for screening purposes.
333
Standard Letter
Participants received a standard of care letter that tells the participant they are out of date with their cervical cancer screening and should contact their primary care provider to schedule an appointment.
631
Total964

Baseline characteristics

CharacteristicModified Letter With Self-sampling Request CardStandard LetterTotal
Age, Customized
30-65 years
333 participants631 participants964 participants
Ethnicity (NIH/OMB)
Hispanic or Latino
189 Participants359 Participants548 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
122 Participants239 Participants361 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
22 Participants33 Participants55 Participants
Insurance type
Missing
20 Participants44 Participants64 Participants
Insurance type
other
267 Participants512 Participants779 Participants
Insurance type
private
46 Participants75 Participants121 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Asian
0 Participants3 Participants3 Participants
Race (NIH/OMB)
Black or African American
36 Participants56 Participants92 Participants
Race (NIH/OMB)
More than one race
46 Participants80 Participants126 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Unknown or Not Reported
169 Participants315 Participants484 Participants
Race (NIH/OMB)
White
82 Participants175 Participants257 Participants
Region of Enrollment
United States
333 participants631 participants964 participants
Sex: Female, Male
Female
333 Participants631 Participants964 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 3330 / 631
other
Total, other adverse events
0 / 3330 / 631
serious
Total, serious adverse events
0 / 3330 / 631

Outcome results

Primary

Percentage of Cervical Cancer Screening

To compare the percentage of cervical cancer screenings completed in the control group who received a standard letter with the percentage of cervical cancer screenings completed in the intervention group who receive a modified letter with a self-sampling option.

Time frame: Three months after the letter is sent.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Modified Letter With Self-sampling Request CardPercentage of Cervical Cancer Screening40 Participants
Standard LetterPercentage of Cervical Cancer Screening95 Participants
Primary

Use of the Self-sampling Kit

Evaluate the number of participants request and use the self-sampling kit in the intervention group.

Time frame: Three months after the letter is sent

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Modified Letter With Self-sampling Request CardUse of the Self-sampling Kit2 Participants
Secondary

Overall Rate of Cervical Cancer Screening Over Both the Control and Intervention Group

Overall rate of cervical cancer screenings for both the control group and the intervention group.

Time frame: Three months after the letter is sent

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Modified Letter With Self-sampling Request CardOverall Rate of Cervical Cancer Screening Over Both the Control and Intervention Group135 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026